John Vavricka - Jan 31, 2025 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role: Chief Commercial Officer
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
Stock symbol: AVIR
Transactions as of: Jan 31, 2025
Transactions value $: -$35,242
Form type: 4
Date filed: 2/4/2025, 06:00 PM
Previous filing: Feb 2, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVIR	Common Stock	Options Exercise		+33.3K	+154.93%		54.8K	Jan 31, 2025	Direct	F1
transaction	AVIR	Common Stock	Award		+8.75K	+15.95%		63.6K	Jan 31, 2025	Direct	F2
transaction	AVIR	Common Stock	Tax liability	-$35.2K	-11.5K	-18.11%	$3.06	52.1K	Jan 31, 2025	Direct
holding	AVIR	Common Stock						82.5K	Jan 31, 2025	Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVIR	Restricted Stock Units	Options Exercise	$0	-33.3K	-50%	$0.00	33.3K	Jan 31, 2025	Common Stock	33.3K		Direct	F1, F3
transaction	AVIR	Restricted Stock Units	Award	$0	+8.75K		$0.00	8.75K	Jan 31, 2025	Common Stock	8.75K		Direct	F1, F4
transaction	AVIR	Stock Option (Right to Buy)	Award	$0	+133K		$0.00	133K	Jan 31, 2025	Common Stock	133K	$3.06	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").
F3	The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
F4	Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.
F5	The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.